Skip to content
PeptideAgent

Peptide blends

Blends such as GLOW, KLOW, and the Wolverine stack put two or more peptides in one vial under a catchy name. None of the 6 blends below has been tested as a combination in a published study, so each page grades every ingredient on its own and shows the legal status the mix inherits from its strictest ingredient.

By the PeptideAgent Editorial Team. Draft, pending editorial review.  Last verified

All blends

Peptide blends with their ingredients, legal status, and WADA status
BlendIngredientsLegal statusWADA
CJC-1295 and ipamorelinCJC-1295 and IpamorelinRegulatory: No lawful pathWADA: WADA prohibited
GLOWGHK-Cu, BPC-157, and TB-500 (thymosin beta-4)Regulatory: No lawful pathWADA: WADA prohibited
KLOWGHK-Cu, BPC-157, TB-500 (thymosin beta-4), and KPVRegulatory: No lawful pathWADA: WADA prohibited
Sermorelin and ipamorelinSermorelin and IpamorelinRegulatory: No lawful pathWADA: WADA prohibited
Tesamorelin and ipamorelinTesamorelin and IpamorelinRegulatory: No lawful pathWADA: WADA prohibited
Wolverine stackBPC-157 and TB-500 (thymosin beta-4)Regulatory: Awaiting FDA final ruleWADA: WADA prohibited

What is in each blend?

CJC-1295 and ipamorelin

CJC-1295 and ipamorelin is a popular pairing of a long-acting GHRH analog with a selective ghrelin receptor agonist, sold premixed or as two vials to raise growth hormone. No study has tested the combination: CJC-1295 has small hormone trials, and ipamorelin has one small growth hormone pharmacology study in healthy men, while its only randomized trial was negative for a surgical use. Neither peptide can be lawfully compounded in the United States.

GLOW

GLOW is a nickname for a premixed injectable of three peptides: GHK-Cu, BPC-157, and TB-500. No published study has tested the combination in people or animals, so each ingredient is graded on its own below. Because injectable GHK-Cu has no lawful compounding path in the United States, the blend has none either.

KLOW

KLOW is a nickname for a premixed injectable of four peptides: the three in GLOW (GHK-Cu, BPC-157, and TB-500) plus KPV, an anti-inflammatory fragment of alpha-MSH. No study has tested the combination, and KPV itself has no human trial. The blend has no lawful path because injectable GHK-Cu has none.

Sermorelin and ipamorelin

Sermorelin and ipamorelin is a pairing of GHRH(1-29), once sold as the approved drug Geref, with the ghrelin receptor agonist ipamorelin, marketed to raise growth hormone. No study has tested the combination. Sermorelin's compounding status is unsettled and ipamorelin has no lawful path, so the blend cannot be lawfully compounded.

Tesamorelin and ipamorelin

The tesamorelin and ipamorelin blend pairs an FDA approved GHRH analog (Egrifta) with an unapproved ghrelin receptor agonist to raise growth hormone. No study has tested the combination. Tesamorelin alone has a lawful prescription path as Egrifta WR; the blend does not, because neither ingredient can be lawfully compounded.

Wolverine stack

The Wolverine stack is a nickname for BPC-157 and TB-500 used together, sold premixed or as two vials, for injury recovery. No study has tested the pair, and both peptides rest mainly on animal data. Both were recommended for the 503A bulks list in July 2026, but neither can be lawfully compounded until FDA publishes a final rule.

For how the most searched blends differ, read KLOW vs GLOW; for why no stack has trial evidence, read peptide stacks ranked by the evidence for each part.

How to read a blend page

A blend is only as well studied as its least studied ingredient, and usually less: mixing peptides raises questions about stability, interactions, and combined side effects that no single-peptide study answers. It is also only as lawful as its least lawful ingredient. A licensed pharmacy cannot compound a mix if any one component is ineligible, so one unlisted peptide makes the whole vial unlawful to compound.

Blend pages never give doses, ratios, or instructions, and never name sellers. For each ingredient's full evidence, see the peptide index; for head-to-head evidence, see the comparisons; for the rules where you live, see peptide laws by state.